New developments in thyroid cancer

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 11, Issue 5 SUPPL., 2013, Pages 705-707

  Haddad, Robert I ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CABOZANTINIB; LENVATINIB; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PACLITAXEL; PLACEBO; RADIOACTIVE IODINE; SELUMETINIB; SORAFENIB; VANDETANIB;

ANAPLASTIC THYROID CANCER; CONFERENCE PAPER; DIARRHEA; DRUG APPROVAL; FATIGUE; HUMAN; HYPERTENSION; METASTASIS; PROGRESSION FREE SURVIVAL; PROTEINURIA; QT PROLONGATION; QUALITY OF LIFE; RASH; SIDE EFFECT; SUDDEN DEATH; THYROID CANCER; THYROID MEDULLARY CARCINOMA; TORSADE DES POINTES; TREATMENT OUTCOME;

EID: 84883153881     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2013.0207     Document Type: Conference Paper

References (8)

1. Enewold L, Zhu K, Ron E, et al. Rising thyroid cancer incidence in the United States by demographic and tumor characteristics, 1980-2005. Cancer Epidemiol Biomark Prev 2009;18:784-791.
2. Bible KC, Suman VJ, Molina JR, et al. Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study. Lancet Oncol 2010;11:962-972.
3. Gupta-Abramson V, Troxel AB, Nellore A, et al. Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol 2008;26:4714-4719.
4. Schlumberger M, Jarzab B, Cabanillas ME, et al. A phase II trial of the multitargeted kinase inhibitor lenvatinib (E7080) in advanced medullary thyroid cancer [abstract]. J Clin Oncol 2012;30(Suppl 15): Abstract 5591.
5. Chakravarty D, Santos E, Ryder M, et al. Small-molecular MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation. J Clin Invest 2011;121:4700-4711.
6. Ho AL, Grewal RK, Leboeuf R, et al. Reacquisition of RAI incorporation of RAI-refractory metastatic thyroid cancers by pretreatment with the selective MEK inhibitor selumetinib (AZD6244): a pilot study. N Engl J Med 2013;368:623-632.
7. Schoffski P, Elisei R, Muller S, et al. An international, double-blind, randomized, placebo-controlled phase III trial (EXAM) of cabozantinib (XL184) in medullary thyroid carcinoma patients with documented RECIST progression at baseline [abstract]. J Clin Oncol 2011;29(Suppl 15): Abstract 5508.
8. Walls SA Jr, Robinson BG, Gagel RF, et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol 2012;30:134-141.